(-0.11%) 5 094.32 points
(0.04%) 38 254 points
(-0.14%) 15 905 points
(-1.30%) $82.76
(5.93%) $2.04
(0.20%) $2 352.00
(-0.38%) $27.43
(3.70%) $956.25
(-0.17%) $0.933
(-0.26%) $11.00
(-0.46%) $0.797
(1.69%) $93.43
0.34% INR 1 088.00
Live Chart Being Loaded With Signals
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India...
Stats | |
---|---|
Dagens volum | 51 600.00 |
Gjennomsnittsvolum | 243 717 |
Markedsverdi | 55.18B |
EPS | INR0 ( 2024-02-09 ) |
Neste inntjeningsdato | ( INR0 ) 2024-05-07 |
Last Dividend | INR3.00 ( 2012-09-13 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 38.15 |
ATR14 | INR0.869 (0.08%) |
Volum Korrelasjon
Orchid Pharma Limited Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Orchid Pharma Limited Korrelasjon - Valuta/Råvare
Orchid Pharma Limited Økonomi
Annual | 2022 |
Omsetning: | INR6.66B |
Bruttogevinst: | INR2.81B (42.24 %) |
EPS: | INR11.35 |
FY | 2022 |
Omsetning: | INR6.66B |
Bruttogevinst: | INR2.81B (42.24 %) |
EPS: | INR11.35 |
FY | 2022 |
Omsetning: | INR5.60B |
Bruttogevinst: | INR2.33B (41.69 %) |
EPS: | INR-0.350 |
FY | 2021 |
Omsetning: | INR4.50B |
Bruttogevinst: | INR2.10B (46.68 %) |
EPS: | INR-28.55 |
Financial Reports:
No articles found.
Orchid Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR2.67 | 2002-07-16 |
Last Dividend | INR3.00 | 2012-09-13 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | INR36.67 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.66 | -- |
Div. Sustainability Score | 4.51 | |
Div.Growth Potential Score | 2.48 | |
Div. Directional Score | 3.50 | -- |
Year | Amount | Yield |
---|---|---|
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SYMPHONY.NS | Dividend Junior | 2023-08-04 | Semi-Annually | 14 | 0.47% | |
NESCO.NS | Dividend Junior | 2023-07-28 | Annually | 17 | 0.40% | |
IDBI.NS | Dividend Junior | 2023-07-06 | Sporadic | 27 | 0.48% | |
CERA.NS | Dividend Junior | 2023-06-20 | Annually | 17 | 0.39% | |
RVNL.NS | Dividend Knight | 2023-09-20 | Annually | 6 | 3.08% | |
LSIL.NS | Dividend Junior | 2023-07-17 | Annually | 3 | 0.23% | |
GEOJITFSL.NS | Dividend Knight | 2023-06-30 | Annually | 20 | 2.79% | |
ARVIND.NS | Dividend Junior | 2023-07-21 | Sporadic | 20 | 0.59% | |
THEMISMED.NS | Dividend Junior | 2023-08-31 | Sporadic | 18 | 0.39% | |
ORIENTELEC.NS | Dividend Junior | 2023-07-26 | Semi-Annually | 7 | 0.41% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.145 | 1.500 | 7.10 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.131 | 1.500 | 9.65 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 5.21 | 1.000 | 9.18 | 9.18 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.63 | 2.00 | 5.79 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.63 | 2.00 | 3.69 | 7.37 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.415 | 1.000 | 6.42 | 6.42 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.131 | 1.000 | 9.38 | 9.38 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 47.69 | 1.000 | 5.28 | 0 | [1 - 100] |
returnOnEquityTTM | 0.131 | 2.50 | 9.78 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.63 | 2.00 | 5.79 | 7.37 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.63 | 2.00 | 5.79 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.269 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0789 | 1.000 | -0.528 | 0 | [0.1 - 0.5] |
Total Score | 2.48 |
Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company's multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. In addition, the company provides liaising support to customers in regulatory, pharma covigilance, testing and release, retention of samples, service providers, and business development. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited is a subsidiary of Dhanuka Laboratories Limited.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.